{"entity":{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","aka":[],"tldr":"CheckMate 743 was the first immunotherapy trial to lengthen survival in mesothelioma, and gave the first new first-line option in 16 years.","summary":"CheckMate 743, trial NCT02899299 sponsored by Bristol Myers Squibb and reported in 2020, was the first immunotherapy trial to lengthen survival in unresectable pleural mesothelioma, giving the first new first-line option in sixteen years. It randomised 605 patients to nivolumab plus ipilimumab or platinum and pemetrexed, met its primary overall survival endpoint with a durable minority alive at five years and the largest benefit in non-epithelioid histology, and led to FDA approval in October 2020 with severe treatment-related events in about a third. OnCo links it to mesothelioma, nivolumab, ipilimumab, pemetrexed, the histology term, Paul Baas, Solange Peters and the pairing of histology with first-line choice. Whether epithelioid patients gain enough to justify dual immunotherapy over chemotherapy combinations is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02899299","url":"https://clinicaltrials.gov/study/NCT02899299"}],"tags":[],"related":[],"cancers":["mesothelioma","pleural-mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab","pemetrexed"],"companies":[],"institutions":[],"pathways":[],"terms":["epithelioid-vs-sarcomatoid"],"trials":[],"people":["paul-baas","solange-peters"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02899299","phase":"3","setting":"Unresectable pleural mesothelioma, first line: nivolumab + ipilimumab vs platinum-pemetrexed","sponsor":"BMS","result":"OS 18.1 vs 14.1 months, HR 0.74; 5-year OS 14% vs 6%.","started":"2016-11-29","startedType":"actual","yearReported":2020,"enrolled":605,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Nivolumab + ipilimumab","n":303,"value":18.1},{"name":"Platinum + pemetrexed","n":302,"value":14.1}],"hr":0.74,"ci":[0.6,0.91],"p":"0.002","source":"https://pubmed.ncbi.nlm.nih.gov/33485464/"},{"endpoint":"5-year overall survival rate","unit":"%","arms":[{"name":"Nivolumab + ipilimumab","value":14},{"name":"Platinum + pemetrexed","value":6}],"hr":0.74,"ci":[0.62,0.88],"source":"https://ascopubs.org/doi/10.1200/JCO-25-01328"}],"replication":"Single phase 3; consistent direction in the phase 2 MAPS2 and INITIATE studies of second-line nivolumab-ipilimumab."},"route":"/trials/checkmate-743/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/"}],"person":[{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/"},{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/"}],"pairing":[{"id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/"}],"paper":[{"id":"paper-checkmate-743-lancet-2021","kind":"paper","name":"CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma","route":"/key-papers/paper-checkmate-743-lancet-2021/"}]}}